American Association for Cancer Research

AACR in the News

Napoleone Ferrara, M.D., is the New Editor-in-Chief of Molecular Cancer Therapeutics, a Journal of the American Association for Cancer Research


September 30, 2013

Bookmark and Share

PHILADELPHIA — The American Association for Cancer Research (AACR) is pleased to announce the appointment of Napoleone Ferrara, M.D., as editor-in-chief of Molecular Cancer Therapeutics, one of the eight peer reviewed journals published by the AACR. In his role, Ferrara will be responsible for setting goals and editorial strategy for the journal. Napoleone Ferrara, M.D.

Molecular Cancer Therapeutics publishes original studies, reviews, and commentaries in the categories of therapeutic discovery, preclinical development, and molecular medicine in practice. The journal provides a publication outlet for these emerging disciplines focused specifically on cancer research.

“Dr. Ferrara is a world-renowned cancer researcher, and the American Association for Cancer Research is delighted to welcome him to the position of editor-in-chief of Molecular Cancer Therapeutics,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “His extraordinary expertise in basic cancer research and anticancer drug development, coupled with his substantial experience in publishing cutting-edge peer-reviewed articles in the field, will help us build on the journal’s success and enhance the exchange of knowledge among scientists.”

Ferrara presently serves as professor of pathology and senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, and his team focuses on investigating mechanisms of tumor angiogenesis. His pioneering research in 1989, for which he has received many accolades, led to the identification of vascular endothelial growth factor (VEGF) gene and the development of two FDA-approved drugs: anti-VEGF monoclonal antibody bevacizumab (Avastin) as a cancer therapy, and anti-VEGF monoclonal antibody fragment ranibizumab (Lucentis) for the treatment of age-related macular degeneration.

“We at the AACR are excited to have the opportunity to work with Dr. Ferrara to help advance therapeutic discoveries and preclinical development through this publication outlet,” said Christine Rullo, publisher and head of the AACR Publishing Division.

Ferrara held various scientific positions at Genentech Inc., in South San Francisco, Calif., between 1988 and 2012, prior to which he served as a postdoctoral research fellow at the Cancer Research Institute at the University of California, San Francisco. He has delivered more than 200 invited presentations; published more than 200 original articles, 75 reviews, and 42 book chapters; and holds 70 patents. He has received numerous awards, including the Pezcoller Foundation-AACR International Award in 2009, the Lasker-DeBakey Clinical Medical Research Award in 2010, and most recently, the Breakthrough Prize in Life Sciences in 2013. Ferrara obtained his degree in medicine from the University of Catania Medical School in Italy.

Molecular Cancer Therapeutics, with its unique focus on drug discovery and preclinical development, and an emphasis on quality rather than quantity, has a strong position in the landscape of oncology journals,” said Ferrara. “I am very enthusiastic about the opportunity to serve as the editor-in-chief, and to work toward the vision of making this journal the top choice for publishing the best oncology drug discovery and preclinical studies among oncology journals.”

In addition to Molecular Cancer Therapeutics, the AACR publishes Cancer Discovery; Cancer Epidemiology, Biomarkers & Prevention; Cancer Immunology Research; Cancer Prevention Research; Cancer Research; Clinical Cancer Research; and Molecular Cancer Research.